Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor ( PAF ) receptor antagonist with IC 50 s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca 2+ influx and intracellular Ca 2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Platelet-activating Factor Receptor (PAFR)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye